DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Denosumab and Teriparatide Study (DATA-2)

Information source: Massachusetts General Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Postmenopausal Osteoporosis

Intervention: denosumab (Drug); teriparatide (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Massachusetts General Hospital

Official(s) and/or principal investigator(s):
Benjamin Leder, MD, Principal Investigator, Affiliation: Massachusetts General Hospital

Overall contact:
Joy Tsai, MD, Phone: 617-726-4650

Summary

The aim of the study is to assess the effect of an antiresorptive medication in combination with standard dose or alternate dose teriparatide.

Clinical Details

Official title: Denosumab and Teriparatide Study (DATA-2)

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Spine Bone Mineral Density by Dual X-ray Absorptiometry (DXA)

Eligibility

Minimum age: 45 Years. Maximum age: N/A. Gender(s): Female.

Criteria:

Inclusion Criteria:

- women aged 45+

- postmenopausal

- osteoporotic with high risk of fracture

Exclusion Criteria:

- no significant previous use of bone health modifying treatments

Locations and Contacts

Joy Tsai, MD, Phone: 617-726-4650

Massachusetts General Hospital, Boston, Massachusetts 02114, United States; Recruiting
Paul Wallace, Phone: 617-726-6129
Additional Information

Starting date: August 2014
Last updated: February 2, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017